Catalyst Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Catalyst Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 16.7% ve 11.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.7%

Kazanç büyüme oranı

16.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.2%
Gelir büyüme oranı	11.4%
Gelecekteki özkaynak getirisi	15.2%
Analist kapsamı	Good
Son güncelleme	24 Jan 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Dec 19

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Nov 13

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Nov 07

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CPRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	695	250	328	327	4
12/31/2026	638	231	285	283	6
12/31/2025	563	187	236	238	8
12/31/2024	484	151	177	192	8
9/30/2024	460	143	186	225	N/A
6/30/2024	434	68	79	197	N/A
3/31/2024	411	65	46	163	N/A
12/31/2023	398	71	-136	144	N/A
9/30/2023	348	62	-114	128	N/A
6/30/2023	303	116	-48	124	N/A
3/31/2023	256	99	-53	120	N/A
12/31/2022	214	83	106	116	N/A
9/30/2022	192	67	85	95	N/A
6/30/2022	170	54	75	76	N/A
3/31/2022	154	45	65	65	N/A
12/31/2021	141	39	59	60	N/A
9/30/2021	134	42	53	54	N/A
6/30/2021	127	75	43	44	N/A
3/31/2021	120	72	41	42	N/A
12/31/2020	119	75	45	45	N/A
9/30/2020	118	71	44	44	N/A
6/30/2020	120	42	49	49	N/A
3/31/2020	119	43	50	50	N/A
12/31/2019	102	32	35	35	N/A
9/30/2019	73	9	14	14	N/A
6/30/2019	42	-12	-9	-9	N/A
3/31/2019	13	-29	-28	-28	N/A
12/31/2018	1	-34	-26	-26	N/A
9/30/2018	N/A	-25	-22	-22	N/A
6/30/2018	N/A	-21	N/A	-18	N/A
3/31/2018	N/A	-19	N/A	-16	N/A
12/31/2017	N/A	-18	N/A	-14	N/A
9/30/2017	N/A	-17	N/A	-14	N/A
6/30/2017	N/A	-17	N/A	-15	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-20	N/A	-18	N/A
6/30/2016	N/A	-20	N/A	-20	N/A
3/31/2016	N/A	-20	N/A	-20	N/A
12/31/2015	N/A	-20	N/A	-18	N/A
9/30/2015	N/A	-18	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-16	N/A
3/31/2015	N/A	-17	N/A	-14	N/A
12/31/2014	N/A	-16	N/A	-13	N/A
9/30/2014	N/A	-13	N/A	-13	N/A
6/30/2014	N/A	-14	N/A	-11	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CPRX 'nin tahmini kazanç büyümesi (yıllık 16.7% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: CPRX şirketinin kazançlarının (yıllık 16.7% ) US pazarından (yıllık 15.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CPRX şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: CPRX şirketinin gelirinin (yıllık 11.4% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CPRX şirketinin gelirinin (yıllık 11.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CPRX 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.2 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/30 08:43
Gün Sonu Hisse Fiyatı	2025/01/30 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Catalyst Pharmaceuticals, Inc. 19 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jason Matthew Gerberry	BofA Global Research
Charles Duncan	Cantor Fitzgerald & Co.
Samantha Lynn Semenkow	Citigroup Inc

Catalyst Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Consensus EPS estimates increase by 16%

Price target increased by 8.4% to US$29.57

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

Recent updates

Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc

Catalyst Pharmaceuticals, Inc. Announces Sub- Licensee DyDo Pharma Launches Firapse®? in Japan

Catalyst Pharmaceuticals and SERB S.A. Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Executive VP notifies of intention to sell stock

Co-Founder & Chairman notifies of intention to sell stock

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind